Exhibition
ACHEMA 2024
Exhibition Name
10 -14 June
Exhibition Venue
Ludwig-Erhard-Anlage 1, Frankfurt am Main
Booth No.
Hall 3.1 , C70
As the world's largest flagship event of process industry, ACHEMA Frankfurt am Main, Germany aims to showcase advanced technologies and products in the fields of chemistry, pharmacy, biotechnology, energy and environment, attracting manufacturers, industry experts and engineers from all over the world to discuss the challenges and future development trends of the industry.
About Pharmadule Morimatsu AB
Pharmadule, a globally recognized leader in modular plant and solutions provision, has proudly completed 80 production facilities within the pharmaceutical and biopharmaceutical industries, along with over 300 successful engineering design and validation solutions since its establishment in 1986. With extensive experience in international project delivery and proper understanding of regulatory requirements in different regions, Pharmadule continues to provide a range of engineering and solutions to pharmaceutical and biopharmaceutical clients worldwide. After becoming a member of Morimatsu Group in 2011, Pharmadule Morimatsu AB perfectly integrates modular plants with process thanks to the strong combination, allowing the company to provide clients with higher-quality and faster turnkey solutions. Pharmadule Morimatsu AB has been selected by globally recognized pharmaceutical clients including Eli Lily, Merck, Baxter, GSK, Genentech, AZ and Lonza, to facilitate quicker and more efficient patient treatment plans.
Pharmadule Morimatsu AB will present new project cases and solutions at the exhibition. The company will have an exchange of views with industry professionals on new developments in digital and intelligent turnkey plant solutions, modular facilities, process systems, bioreactors and other products. Look forward to seeing you there!
About Morimatsu LifeSciences
Morimatsu LifeSciences, one of the key business segments of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), mainly consists of Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and its subsidiaries, which serves the pharmaceuticals, bio-pharmaceutical, cosmetic medicine, FMCG (cosmetics, baby, women & home Care, health care, fabric & home care, food, beverage, nutraceuticals) and other industries, providing customers with "core equipment+value-added services+digital intelligent overall factory solutions and services" ("MVP Solutions&Services"), focusing on core equipment, stainless steel process systems, disposable process systems, consumables, laboratory solutions, digital and modular factory solutions and services.
As a diversified multinational company, Morimatsu has opened subsidiaries or advanced manufacture plants in China, Japan, Sweden, United States, India, Italy, Singapore, and has delivered different forms of products and services to more than 40 countries and regions so far, by its global footprint of an efficient and professional team.
Forward-Looking Statements
The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of "predicted", "believed", "forecast", "planned" and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our Company undertakes no obligation to constantly revise such predicted statements.
Forward-looking statements are based on our Company management's current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guarantees of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our Company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.
